About the Company
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SYN News
Theriva Biologics, Inc. (TOVX)
Jan. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas ...
Synthetic Biologics (NYSEMKT: SYN)
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product ...
Theriva Biologics Announces Positive Data From Phase 1 Trial Of VCN-01 In Intraocular Retinoblastoma
(RTTNews) - Theriva Biologics Inc. (TOVX) Tuesday announced positive data from the Phase 1 trial evaluating the safety and tolerability of two intravitreal injections of its investigational oncolytic ...
Buy Recommendation for Theriva Biologics Backed by Promising Oncolytic Adenovirus Platform and Clinical Trial Advancements
Begin your TipRanks Premium journey today. Theriva Biologics (TOVX) Company Description: Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to ...
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
About Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas ...
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
About Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas ...
Theriva Biologics, Inc.: Theriva Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
Theriva Biologics, Inc. Poster Session Date and Time: Friday, May 10, 2024 at 12:00 p.m. ET About Theriva Biologics, Inc. Theriva Biologics. Forward-Looking Statement This release contains forward ...
Q4 2023 Theriva Biologics Inc Earnings Call
Q4 2023 Theriva Biologics Inc Earnings Call Q4 2023 Theriva Biologics Inc Earnings Call HOME MAIL NEWS FINANCE SPORT CELEBRITY STYLE WEATHER MORE... Yahoo Finance Sign in Mail Sign in to view your ...
Theriva Biologics Inc SFY
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Theriva Biologics Inc TOVX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...